Epidarex Capital Invests in Ryme Medical
Epidarex is pleased to announce the addition of Ryme Medical to our portfolio of medtech investments. Ryme is developing a unique catheter-based therapy that seeks to reduce
Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
WALTHAM, Mass. and STOCKHOLM, Aug. 08, 2024 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO: SOBI) today announced positive topline results from the
NodThera Named a ‘Fierce 15’ Company by Fierce Biotech
Philadelphia, PA, August 5, 2024 – NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3
NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer
– Greg brings over 25 years of public and private company leadership experience Philadelphia, PA, August 1, 2024 – NodThera, a leading clinical-stage biotech delivering a paradigm
Lario Therapeutics awarded $6M Grant from The Michael J. Fox Foundation for Parkinson’s Research
Edinburgh, UK, 22 July 2024: Lario Therapeutics (‘Lario’, or ‘the Company’), a biopharmaceutical company developing first-in-class precision medicines for epileptic and neurological disorders, today announced
NodThera’s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint ofInflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk
BOSTON, MA, – NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, today announces positive data from its Phase
Harness Therapeutics appoints Leading World Experts in Neurodegenerative Diseases to its Scientific Advisory Board (SAB)
Newly established SAB of prominent geneticists, biologists and Huntington’s disease specialists’ marks pivotal step in accelerating progress of lead programme HRN001 Cambridge, UK,: Harness Therapeutics,